Imagine if instead of daily glaucoma eye drops, a tiny implant in your eye slowly released medication for months or even years – that’s the promise of sustained-release technology. The iDose TR is one breakthrough example: a micro-sized implant filled with a pressure-lowering drug (a form of travoprost) that is placed inside the eye. It provides a continuous trickle of medication, like an “infusion” for the eye, without you needing to remember drops every day. In fact, clinical studies have shown about 80% of patients with an iDose didn’t need any additional glaucoma drops for at least a year after implantation. This device was recently FDA-approved and can be implanted during a quick procedure (sometimes combined with cataract surgery). The benefit is improved pressure control 24/7 and no adherence issues – the implant never blinks or forgets, unlike humans! Beyond iDose, there are other sustained-release approaches in development or available: tiny dissolvable pellets injected in the eye (for example, a one-time bimatoprost implant that lasts 4-6 months), special punctal plugs that sit in your tear duct slowly releasing drug, or even medicated contact lenses. All these aim to solve one of glaucoma’s biggest challenges: people often struggle with taking drops consistently. By delivering medicine at the site, these implants can also reduce side effects (since less drug washes onto the ocular surface and into the body). Patients ask, “What is it like to have an implant – do I feel it? Can it be removed?” The iDose is so small you won’t feel it, and it’s designed to stay in place long-term, releasing drug until it’s depleted, at which point it can be replaced with a new one if needed. Surgeons can remove or exchange it if necessary. Other implants like the gel pellet (Durysta) dissolve away over time. Clinical considerations: sustained-release is great for those with early to moderate glaucoma needing steady pressure control, or anyone who has trouble with drops (due to arthritis, memory, cost, or irritation). It may not achieve very low pressures like a traditional surgery could, but it can be an excellent middle-ground solution. It’s empowering for patients because it shifts the burden of treatment from daily self-care to a periodic in-office or in-OR procedure. As technology advances, we may even see intraocular lenses that slowly release glaucoma medsafter cataract surgery, or smart implants that you can activate remotely – the horizon is exciting. For now, iDose and similar implants represent a significant innovation to make glaucoma management simpler and more consistent. Visual suggestion: a close-up schematic of the iDose implant inside the eye (perhaps in the scleral wall), with an inset showing an enlarged view of the tiny capsule releasing drug molecules. Additionally, an infographic timeline could illustrate how one implant can continuously control eye pressure for many months versus daily drop spikes, reinforcing the concept of steady drug delivery.